PRME Earnings Results and History
Prime Medicine, Inc.'s earnings at a glance: the latest results and outlook from the press release, revenue, margins and EPS for every quarter from the company's SEC filings, and how the stock moved after each report. New results show here within about a minute of being filed.
- EPS−$0.22 vs −$0.24 est +9.6%
- Revenue–
Filed ยท Press release
Key takeaways
from the press release- First patient dosed in Phase 1/2 trial of PM577a for Wilson disease, the first in vivo Prime Editing clinical study; data expected 2027.
- FDA cleared IND for PM647 in Alpha-1 Antitrypsin Deficiency; initial clinical data expected in 2027.
EPS by quarter
GAAP diluted, 12 quartersRevenue and operating margin
from 10-Q and 10-KQuarter by quarter
from 10-Q and 10-K filings| Quarter ended | Revenue | Growth | Op margin | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| Sep 2026 | $4.2M | +243.9% | −947.7% | −$39M | −$0.22 | −$37M |
| Jun 2026 | – | – | – | −$42.1M | −$0.24 | −$41.1M |
| Mar 2026 | – | – | – | −$49.1M | −$0.28 | −$42.9M |
| Dec 2025 | $838K | −61.6% | −5800.5% | −$46.1M | −$0.24 | −$37.5M |
EPS here is GAAP diluted, as filed with the SEC. Estimates are usually based on adjusted EPS, so the two can differ. Growth compares with the same quarter a year earlier.
Year by year
fiscal years, from 10-K filings| Year ended | Revenue | Growth | Op margin | Net income | EPS |
|---|---|---|---|---|---|
| Dec 31, 2025 | $4.6M | +55.3% | −4498.1% | −$201.1M | −$1.35 |
| Dec 31, 2024 | $3M | – | −6787.4% | −$195.9M | −$1.65 |
| Dec 31, 2023 | $0 | – | – | −$198.1M | −$2.18 |
| Dec 31, 2022 | $0 | – | – | −$121.8M | −$4.19 |
| Dec 31, 2021 | $0 | – | – | −$165.4M | −$14.19 |
Filings and dates
SEC EDGAR- Nov 12, 2026Earnings release, Q3 20268-K Press release
- Nov 12, 2026Quarterly report10-Q All filings
Also see PRME institutional ownership and the earnings calendar.
PRME earnings FAQ
What were PRME's latest earnings?
For Q3 2026 Prime Medicine, Inc. reported, GAAP EPS of -$0.22. The results were filed with the SEC on Nov 12, 2026.
When is PRME's next earnings date?
There is no confirmed date on our calendar yet. Most companies report about four to six weeks after each quarter ends.
Is PRME's revenue growing?
In the quarter ended Sep 30, 2026 revenue was $4.2M, up 243.9% from a year earlier. The table on this page shows every quarter from the company's 10-Q and 10-K filings.
Where do these numbers come from?
Results, guidance and financials come from Prime Medicine, Inc.'s own SEC filings: the earnings press release (Form 8-K) and the quarterly and annual reports (10-Q and 10-K). Key takeaways summarize the press release. Estimates and price moves come from market data.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Results come from company filings with the SEC. Estimates are consensus figures from before each report. Key takeaways summarize the company's press release and may contain errors; the press release is the authoritative source.